Rigel Pharmaceuticals, Inc.
RIGL
Jodie situation report
Rigel Pharmaceuticals, Inc.'s move is spreading beyond its market group.
No new filing conclusion is available. 23 of 23 group members are active now; 1 filing-linked outsider is moving with the group, and 0 of 7 directly disclosed connections are confirming.
- At least 15 of 23 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- BMRN remains aligned with the group in the next market snapshot.
Invalidation: The live read weakens if participation falls to 8 of 23 members or fewer.
Who this business touches
The relationships behind RIGL
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
GRFSFiling-linked namepartnerMay 5, 2026 ▾
“Fostamatinib outside of the US We have a commercialization license agreement with Grifols for exclusive rights to commercialize fostamatinib for human diseases, and non-exclusive rights to develop fostamatinib in their territory.”
AMGNAmgen Inc.partnerNov 4, 2025 ▾
“Other products in the US that are approved by the FDA to increase platelet production through binding to TPO receptors on megakaryocyte precursors include PROMACTA ® (Novartis International AG), Nplate ® (Amgen, Inc.), 31 Table of Contents DOPTELET ® (Swedi…”
Depended on by
NUVBNuvation Bio Inc.competitorMar 2, 2026 ▾
“Another mIDH1 currently in clinical development for mIDH1 glioma is Rigel’s olutasidenib.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 4 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
RIGL is currently a Early Follower in the organic co-movement group Clinical Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.